AbbVie has submitted regulatory applications to both the FDA and the European Medicines Agency for Rinvoq (upadacitinib) to treat adult patients with giant cell arteritis (GCA) https://t.co/LqRcm2FEFV https://t.co/XEjjSNnOGt

• AbbVie Submits Applications for Rinvoq for Giant Cell Arteritis

Full read overview of myositis associated - ILD (and treatments), including: - Case examples - Antisynthetase Syndrome - Anti-MDA5 Amyopathic DM - Interstitial Lung Disease in Myositis https://t.co/zQpfstnGy8 https://t.co/XogyyxuVMk

• A Review of Myositis-Associated Interstitial Lung Disease

Preliminary results from RESET-RA Study announced; demonstrating ACR20 efficacy of implanted vagal nerve stimulation at 12 wks (p=0.0209). 2-staged, multicenter, randomized, sham-controlled, double-blind pivotal trial, enrolled 242 RA pts https://t.co/gIVJd9F6Pk https://t.co/SNjWIa3raB

• SetPoint Medical Announces Positive Topline Results from Landmark RESET-RA Stud…

Study from the UK Biobank (n 459K) shows long-term exposure to air pollutants (PM2.5, PM10, NO2, and NOx) may increase the risk of #SLE. 399 SLE pts (F/U 11.8 yrs) found an 18027% incr SLE risk w/ pollutants; magnified in those with high genetic risk https://t.co/PI4rvKwfpj https://t.co/2CZ28rHVG2

• Air Pollution, Genetic Susceptibility, and Risk of Incident Systemic Lupus Eryt…

Efficacy of Biologics in Patients with CKD A retrospective cohort study of biological bDMARDs persistence in RA patients w/CKD, shows the 3 year survival to be > 50% but all studied biologics were nearly equivalents with regard to safety and efficacy. https://t.co/rL2ZondUsE https://t.co/1hM237Jl83

• Efficacy of Biologics in Patients with Chronic KIdney Disease | RheumNow

In the US CorEvitas registry of 1823 PsA pts; 11.1% fulfilled fibromyalgia definition & 20.6% had widespread pain. FM was assoc w/ female, depression/anxiety, impaired function, increased BMI, comorbidities. cDAPSA, patient pain& TJC https://t.co/YwRBYo1aR6 https://t.co/TXraU0F3Mh

• Prevalence of Fibromyalgia and Widespread Pain in Psoriatic Arthritis: Associat…

FDA adverse event study of JAKi in #RA assoc w/ signif more VTE, ischemic heart Dz, & tachyarrhythmias. 75,407 on JAKi vs 303,278 on biologics (TNFi, RTX, TCZ); JAK had more VTE (ROR=2.11), CVA (ROR=1.25), IHD (1.23), arrhythmias (1.15 ), esp in 1st yr. https://t.co/IVsGwqpiJK https://t.co/4epOHdNHbO

• https://buff.ly/3W1A1KD

Sobi has submitted a biologics license application to FDA for SEL-212 (pegadricase a uricase enzyme that breaks down uric acid) based on DISSOLVE I & II RCTs. SEL-212 was given FDA FDA’s Fast Track designation in March 2024 https://t.co/TPcUnCJOxT https://t.co/X1DrFDJZeK

• Sobi starts rolling FDA filing for chronic gout drug

Full read, comprehensive review of NLRP3 inflammasome & its role in inate immunity (eg, infections), but also lifestyle (obesity, diabetes, NAFLD, heart/lung disease, periodontitis) and autoimmune diseases https://t.co/rCk9ncEsGA https://t.co/qc9eSIAVYe

• NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders

European Research Council has awarded a Proof of Concept Grant to Institute of Bioengineering of Catalonia and their OrthoBots project, to study the treatment of joint diseases using nanorobots to deliver nanoparticle based therapy to synovial tissues https://t.co/JmYQ1727rf https://t.co/k5uZoSwJPo

• Nanorobots capable of travelling through synovial fluid to fight arthritis

ICYMI: Community-Acquired Pneumonia (CAP) https://t.co/geb8y2AK26 https://t.co/cB3y5vQoz1

• ICYMI: Community-Acquired Pneumonia (CAP) | RheumNow

Progress in SLE with new mRNA CAR-T cell Trial Cartesian Therapeutics, has announced their first-in-class mRNA CAR-T therapy has been given to the first SLE. patient in a Phase 2 open-label clinical trial. https://t.co/7SYNtjIn9F https://t.co/a5LJn8QLT3

• Progress in SLE with new mRNA CAR-T cell Trial | RheumNow

Urticarial vasculitis - rare autoimmune dz w/ persistent edematous papules & plaques lasting >24 hrs, w/ systemic Sxs (joint pain, fever). Long-lasting skin lesions tend to leave a bruiselike look. Requires Bx show leukocytoclasticl vasculitis https://t.co/cFWrntrlMw https://t.co/JPkh5FVNo3

• https://buff.ly/4ePG6SW

ICYMI: 2022 EULAR Recommendations on Screening & Prophylaxis for Opportunistic Infections https://t.co/eHn2o2pFFR https://t.co/8S1fzl4AaJ

• ICYMI: 2022 EULAR Recommendations on Screening & Prophylaxis for Opportunistic …